EGFR and non-small cell lung carcinoma: To further improve treatment outcomes, FLAURA2 (NCT04035486) and MARIPOSA-2 (NCT04988295) have initiated a new phase of osimertinib-based combination treatment strategies for first-line treatment of EGFR-mutant NSCLC[30,31].